Tigecycline for the treatment of patients with community-acquired pneumonia requiring hospitalization (Q37608268)

21 August 2017

1 reference

title

Tigecycline for the treatment of patients with community-acquired pneumonia requiring hospitalization (English)

1 reference

21 August 2017

0 references

1 reference

Matthew E Falagas

1 reference

21 August 2017

Eugenios I Metaxas

1 reference

21 August 2017

publication date

1 October 2009

1 reference

Expert Review of Anti-infective Therapy

21 August 2017

published in

1 reference

21 August 2017

1 reference

21 August 2017

1 reference

21 August 2017

page(s)

913-923

1 reference

Treatment costs of community-acquired pneumonia in an employed population

21 August 2017

cites work

1 reference

National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study

21 January 2018

1 reference

Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis

21 January 2018

1 reference

Antimicrobial therapy of community-acquired pneumonia

21 January 2018

1 reference

Community-acquired pneumonia on the intensive care unit: secondary analysis of 17,869 cases in the ICNARC Case Mix Programme Database.

21 January 2018

1 reference

Guidelines for the management of community-acquired pneumonia. Current recommendations and antibiotic selection issues

21 January 2018

1 reference

Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study

21 January 2018

1 reference

A prediction rule to identify low-risk patients with community-acquired pneumonia

21 January 2018

1 reference

Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults

21 January 2018

1 reference

Guidelines for the management of adult lower respiratory tract infections

21 January 2018

1 reference

Short- versus long-course antibacterial therapy for community-acquired pneumonia : a meta-analysis

21 January 2018

1 reference

Adjunctive therapies for community-acquired pneumonia: a systematic review

21 January 2018

1 reference

Antimicrobial activity and pharmacokinetics/pharmacodynamics of the novel glycylcycline, tigecycline

21 January 2018

1 reference

21 January 2018

1 reference

Tigecycline: a new glycylcycline for treatment of serious infections

21 January 2018

1 reference

In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004).

21 January 2018

1 reference

Antipneumococcal activities of GAR-936 (a new glycylcycline) compared to those of nine other agents against penicillin-susceptible and -resistant pneumococci

21 January 2018

1 reference

Activities of tigecycline (GAR-936) against Legionella pneumophila in vitro and in guinea pigs with L. pneumophila pneumonia

21 January 2018

1 reference

Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence

21 January 2018

1 reference

Tigecycline: a glycylcycline antimicrobial agent

21 January 2018

1 reference

Preclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agent.

21 January 2018

1 reference

Tigecycline: an investigational glycylcycline antimicrobial with activity against resistant gram-positive organisms

21 January 2018

1 reference

Tigecycline: clinical evidence and formulary positioning

21 January 2018

1 reference

Tigecycline: a critical analysis

21 January 2018

1 reference

Tigecycline: what is it, and where should it be used?

21 January 2018

1 reference

Mutations in the interdomain loop region of the tetA(A) tetracycline resistance gene increase efflux of minocycline and glycylcyclines

21 January 2018

1 reference

Pharmacokinetics of Tigecycline after Single and Multiple Doses in Healthy Subjects

21 January 2018

1 reference

In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria

21 January 2018

1 reference

The pharmacokinetic and pharmacodynamic profile of tigecycline

21 January 2018

1 reference

Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of tigecycline

21 January 2018

1 reference

In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections

21 January 2018

1 reference

Etiology of community-acquired pneumonia treated in an ambulatory setting

21 January 2018

1 reference

Etiology of community-acquired pneumonia

21 January 2018

1 reference

Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes

21 January 2018

1 reference

Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia

21 January 2018

1 reference

Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibil

21 January 2018

1 reference

Tigecycline therapy significantly reduces the concentrations of inflammatory pulmonary cytokines and chemokines in a murine model of Mycoplasma pneumoniae pneumonia

21 January 2018

1 reference

In vitro activity of GAR-936 against Chlamydia pneumoniae and Chlamydia trachomatis

21 January 2018

1 reference

Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline

21 January 2018

1 reference

Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies

21 January 2018

1 reference

Clinical experience with recently approved antibiotics

21 January 2018

1 reference

Tigecycline in the treatment of infections from multi-drug resistant gram-negative pathogens

21 January 2018

1 reference

Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents

21 January 2018

1 reference

Tigecycline: a new glycylcycline antimicrobial agent

21 January 2018

1 reference

Tigecycline possibly underdosed for the treatment of pneumonia: a pharmacokinetic viewpoint

21 January 2018

1 reference

Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia

21 January 2018

1 reference

Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin

21 January 2018

1 reference

Tigecycline versus levofloxacin for the treatment of community-acquired pneumonia: European experience

21 January 2018

1 reference

Safety of newer parenteral antibiotics

21 January 2018

1 reference

In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004).

21 January 2018

1 reference

Antimicrobial susceptibility among pathogens collected from hospitalized patients in the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial

21 January 2018

1 reference

Tigecycline: a first in class glycylcycline

21 January 2018

1 reference

Factors Predicting Mortality in Necrotizing Community-Acquired Pneumonia Caused by Staphylococcus aureus Containing Panton-Valentine Leukocidin

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERI.09.73

1 reference

21 August 2017

1 reference